Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Viral protease inhibitors.

Anderson J, Schiffer C, Lee SK, Swanstrom R.

Handb Exp Pharmacol. 2009;(189):85-110. doi: 10.1007/978-3-540-79086-0_4. Review.

PMID:
19048198
2.
3.

Combinations of cyclophilin inhibitor NIM811 with hepatitis C Virus NS3-4A Protease or NS5B polymerase inhibitors enhance antiviral activity and suppress the emergence of resistance.

Mathy JE, Ma S, Compton T, Lin K.

Antimicrob Agents Chemother. 2008 Sep;52(9):3267-75. doi: 10.1128/AAC.00498-08. Epub 2008 Jun 30.

4.

Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease.

Lin C, Kwong AD, Perni RB.

Infect Disord Drug Targets. 2006 Mar;6(1):3-16. Review.

PMID:
16787300
5.

A review of HCV protease inhibitors.

Chen KX, Njoroge FG.

Curr Opin Investig Drugs. 2009 Aug;10(8):821-37. Review.

PMID:
19649927
6.

Hepatitis C virus resistance to protease inhibitors.

Halfon P, Locarnini S.

J Hepatol. 2011 Jul;55(1):192-206. doi: 10.1016/j.jhep.2011.01.011. Epub 2011 Feb 1. Review.

7.

Antiviral drug discovery targeting to viral proteases.

Hsu JT, Wang HC, Chen GW, Shih SR.

Curr Pharm Des. 2006;12(11):1301-14. Review.

PMID:
16611117
8.

Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.

López-Labrador FX, Moya A, Gonzàlez-Candelas F.

Antivir Ther. 2008;13(4):481-94.

PMID:
18672527
9.

Inhibiting viral proteases: challenges and opportunities.

Bianchi E, Pessi A.

Biopolymers. 2002;66(2):101-14. Review.

PMID:
12325160
10.

Drug design targeting the main protease, the Achilles' heel of coronaviruses.

Yang H, Bartlam M, Rao Z.

Curr Pharm Des. 2006;12(35):4573-90. Review.

PMID:
17168763
11.

Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors.

Kwong AD, McNair L, Jacobson I, George S.

Curr Opin Pharmacol. 2008 Oct;8(5):522-31. doi: 10.1016/j.coph.2008.09.007. Epub 2008 Oct 17. Review.

PMID:
18835365
12.

Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus.

Tsantrizos YS.

Acc Chem Res. 2008 Oct;41(10):1252-63. doi: 10.1021/ar8000519. Epub 2008 Aug 6.

PMID:
18681464
13.

Protease Inhibitors Block Multiple Functions of the NS3/4A Protease-Helicase during the Hepatitis C Virus Life Cycle.

McGivern DR, Masaki T, Lovell W, Hamlett C, Saalau-Bethell S, Graham B.

J Virol. 2015 May;89(10):5362-70. doi: 10.1128/JVI.03188-14. Epub 2015 Mar 4.

14.

High-throughput screening (HTS) and hit validation to identify small molecule inhibitors with activity against NS3/4A proteases from multiple hepatitis C virus genotypes.

Lee H, Zhu T, Patel K, Zhang YY, Truong L, Hevener KE, Gatuz JL, Subramanya G, Jeong HY, Uprichard SL, Johnson ME.

PLoS One. 2013 Oct 9;8(10):e75144. doi: 10.1371/journal.pone.0075144. eCollection 2013.

15.

Viral proteinases--possible targets of antiviral drugs.

Maliar T, Baláz S, Tandlich R, Sturdík E.

Acta Virol. 2002;46(3):131-40. Review.

PMID:
12580374
16.

Hepatitis C virus NS3-4A protease inhibitors: countering viral subversion in vitro and showing promise in the clinic.

Thomson JA, Perni RB.

Curr Opin Drug Discov Devel. 2006 Sep;9(5):606-17. Review.

PMID:
17002221
17.

Synergy of a hepatitis C virus (HCV) NS4A antagonist in combination with HCV protease and polymerase inhibitors.

Wyles DL, Kaihara KA, Schooley RT.

Antimicrob Agents Chemother. 2008 May;52(5):1862-4. doi: 10.1128/AAC.01208-07. Epub 2008 Mar 10.

18.

A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors.

Chase R, Skelton A, Xia E, Curry S, Liu S, McMonagle P, Huang HC, Tong X.

Antiviral Res. 2009 Nov;84(2):178-84. doi: 10.1016/j.antiviral.2009.09.003. Epub 2009 Sep 10.

PMID:
19747948
19.

Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.

Dahl G, Sandström A, Akerblom E, Danielson UH.

Antivir Ther. 2007;12(5):733-40.

PMID:
17713156
20.

Selection of replicon variants resistant to ACH-806, a novel hepatitis C virus inhibitor with no cross-resistance to NS3 protease and NS5B polymerase inhibitors.

Yang W, Zhao Y, Fabrycki J, Hou X, Nie X, Sanchez A, Phadke A, Deshpande M, Agarwal A, Huang M.

Antimicrob Agents Chemother. 2008 Jun;52(6):2043-52. doi: 10.1128/AAC.01548-07. Epub 2008 Apr 14.

Supplemental Content

Support Center